Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Bellicum Pharmaceuticals, Inc. (BLCM)

1.21   -0.01 (-0.82%) 06-26 19:55
Open: 1.2 Pre. Close: 1.22
High: 1.25 Low: 1.2
Volume: 7,956 Market Cap: 10(M)
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.25 - 1.26 1.26 - 1.26
Low: 1.18 - 1.19 1.19 - 1.2
Close: 1.2 - 1.21 1.21 - 1.22

Technical analysis

as of: 2022-06-24 4:38:26 PM
Overall:       
Stoxline posted a BUY today, downgraded from strong buy. Upward movement continues, but could change at any time.
Target: Six months: 1.52     One year: 1.75
Support: Support1: 1    Support2: 0.83
Resistance: Resistance1: 1.3    Resistance2: 1.5
Pivot: 1.14
Moving Average: MA(5): 1.12     MA(20): 1.2
MA(100): 1.59     MA(250): 2.05
MACD: MACD(12,26): -0.1     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 46     %D(3): 28
RSI: RSI(14): 47.4
52-week: High: 4.03  Low: 1
Average Vol(K): 3-Month: 27 (K)  10-Days: 22 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ BLCM ] has closed below upper band by 25.3%. Bollinger Bands are 40.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Wed, 22 Jun 2022
StockNews.com Initiates Coverage on Bellicum Pharmaceuticals (NASDAQ:BLCM) - Defense World

Tue, 14 Jun 2022
Bellicum Pharmaceuticals (NASDAQ:BLCM) Coverage Initiated by Analysts at StockNews.com - Defense World

Wed, 08 Jun 2022
Reading and writing habits compensate for aging effects in speech connectedness | npj Science of Learning - Nature.com

Tue, 07 Jun 2022
Where Does Bellicum Pharmaceuticals Inc (BLCM) Stock Fall in the Biotechnology Field After It Is Down -29.08% This Week? - InvestorsObserver

Thu, 24 Mar 2022
Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update - GlobeNewswire

Wed, 26 Jan 2022
Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 8 (M)
Shares Float 7 (M)
% Held by Insiders 1.6 (%)
% Held by Institutions 30.3 (%)
Shares Short 200 (K)
Shares Short P.Month 233 (K)

Stock Financials

EPS 0.68
EPS Est Next Qtl -0.75
EPS Est This Year -3.02
EPS Est Next Year -2.96
Book Value (p.s.) -1.46
Profit Margin (%) -156.6
Operating Margin (%) -393.4
Return on Assets (ttm) -34
Return on Equity (ttm) -33.5
Qtrly Rev. Growth 0
Gross Profit (p.s.) -2.07
Sales Per Share 0.73
EBITDA (p.s.) -2.9
Qtrly Earnings Growth -93.4
Operating Cash Flow -23 (M)
Levered Free Cash Flow -28 (M)

Stock Valuations

PE Ratio 1.76
PEG Ratio 0
Price to Book value -0.84
Price to Sales 1.63
Price to Cash Flow -0.44

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2020-02-05
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.